Therapeutic area intelligence for Nutritional Deficiency with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

Mankind Pharma →

Assets

Aspiro →

Mankind →

Recent signals(2)

RegulatoryAugust 6, 2026

Mankind Pharma's ANDA220513 for Thiamine Hydrochloride Receives AP Status

Mankind Pharma's application ANDA220513 for Thiamine Hydrochloride has received an Approval Pending (AP) status.

RegulatoryJuly 15, 2026

FDA Grants Approval for Cyancobalamin ANDA219820 by Aspiro

The FDA has granted approval for the ANDA219820 application for Cyancobalamin submitted by Aspiro.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.